<DOC>
	<DOC>NCT00348881</DOC>
	<brief_summary>This is a study to compare the safety and immune response of a pentavalent DTaP-HB-PRP~T combined vaccine with Tritanrix-HepB/Hib™, when both are given concomitantly with OPV at 6, 10, and 14 weeks of age.</brief_summary>
	<brief_title>Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>At Screening: 0 to 3 day old infants Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg Apgar score ≥ 7 at three minutes after birth Informed consent form signed by one parent or legal representative if appropriate (independent witness mandatory if parent is illiterate) At Inclusion: Six weeks of age Received a dose of Hepatitis B (HB) in the first three days of life Able to attend all scheduled visits and to comply with all trial procedures. At Screening: Illness at a stage that could interfere with trial conduct or completion Any vaccination before HB vaccination (except bacille CalmetteGuérin [BCG] given at birth) Vaccination planned in the 4 to 6 weeks following the first trial vaccination (except BCG if not given at birth) Acute illness on the day of screening. At Screening and at Inclusion: Blood or bloodderived products received since birth Planned participation in another clinical trial during the present trial period Mother known as seropositive to Human immunodeficiency virus (HIV) or Hepatitis C, or as carrying the HB surface antigen (HBsAg) Known thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination Known hypersensitivity to any component of any vaccine to be used in the trial (including neomycin and polymixin B) At Inclusion: Nontrial vaccine administered since birth, except Bacille CalmetteGuérin (BCG) Participation in another clinical trial before the first trial vaccination Congenital or acquired immunodeficiency, immunosuppressive therapy such as longterm systemic corticosteroid therapy Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances Chronic illness at a stage that could interfere with trial conduct or completion Vaccination other than with the study vaccines planned in the 12 weeks following inclusion Documented history of pertussis, tetanus, diphtheria, polio, H. influenza type b, or HB infection (confirmed clinically, serologically, or microbiologically) History of seizures Febrile (rectal temperature ≥ 38.0°C) or acute illness on the day of inclusion.</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>50 Days</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Hepatitis B Hansenula (HB)</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
</DOC>